Drug intelligence / Profile preview

ZS-1001

Development stage: Preclinical
Lead developer: Genuine Biotech
Modality: Small Molecules

Overview

ZS-1001 is a small-molecule agonist of the Stimulator of Interferon Genes (STING) protein, currently under development by Bio Genuine (GenuineBiotech) for the treatment of solid and malignant tumors. By targeting the cyclic GMP-AMP synthase (cGAS)-STING signaling pathway, ZS-1001 mimics the effect of cytosolic DNA to trigger the production of type I interferons and other pro-inflammatory cytokines. This activation enhances the recruitment and maturation of antigen-presenting cells (APCs), subsequently priming and activating tumor-specific T cells to induce a robust anti-tumor immune response. ZS-1001 is part of Bio Genuine's research pipeline focused on innovative oncology therapeutics.

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on ZS-1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZS-1001.

Explore the full profile